Table 1 Indications and dosages of ICIs
From: Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Target | Drug | Half-life | Regimen | Indication | First approved doses | Current approved doses |
|---|---|---|---|---|---|---|
CTLA-4 | Ipilimumab | ~15 days | Monotherapy | Advanced melanoma | 3Â mg/kg Q3W total of 4 doses | |
Monotherapy | Adjuvant melanoma* | 10Â mg/kg Q3W for 4 doses followed by 10Â mg/kg Q12W up to 3Â years | ||||
In combination with nivolumab | Advanced melanoma HCC* | 3Â mg/kg Q3W total of 4 doses | ||||
Advanced RCC MSI-H/dMMr mCRC | 1Â mg/kg Q3W total of 4 doses | |||||
mNSCLC* mesothelioma | 1Â mg/kg Q6W up to 2Â years | |||||
In combination with nivolumab and chemotherapy | mNSCLC | 1Â mg/kg Q6W up to 2Â years | ||||
PD-1 | Nivolumab | ~25 days | Monotherapy | Advanced melanoma mNSCLC Advanced RCC Hodgkin lymphoma HNSCC Urothelial carcinoma HCC* Esophageal cancer MSI-H/dMMr mCRC* | 3 mg/kg Q2W | 240 mg Q2W or 480 mg Q4W†|
Adjuvant melanoma Adjuvant Esophageal or GEJ cancer | 240 mg Q2W or 480 mg Q4W†up to 1 year | |||||
MSI-H/dMMr mCRC (< 40 kg)* | 3 mg/kg Q2W | |||||
In combination with ipilimumab | Advanced melanoma HCC* | 1Â mg/kg Q3W for 4 doses followed by 3Â mg/kg Q2W | 1Â mg/kg Q3W for 4 doses followed by 240Â mg Q2W or 480Â mg Q4W | |||
mNSCLC* | 3Â mg/kg Q2W up to 2Â years | |||||
Mesothelioma | 3Â mg/kg Q2W | 360Â mg Q3W up to 2Â years | ||||
Advanced RCC MSI-H/dMMr mCRC | 3Â mg/kg Q3W for 4 doses followed by 3Â mg/kg Q2W | 3Â mg/kg Q3W for 4 doses followed by 240Â mg Q2W or 480Â mg Q4W | ||||
MSI-H/dMMr mCRC (< 40 kg) | 3 mg/kg Q2W | |||||
In combination with ipilimumab and chemotherapy | mNSCLC | 360Â mg Q3W up to 2Â years | ||||
In combination with cabozantinib | Advanced RCC | 240Â mg Q2W up to 2Â years | 240Â mg Q2W or 480Â mg Q4W up to 2Â years | |||
In combination with chemotherapy | Gastric, GEJ, Esophageal cancer* | 240Â mg Q2W or 360Â mg Q3W up to 2Â years | ||||
Pembrolizumab | ~25 days | Monotherapy | Advanced melanoma mNSCLC mSCLC* Hodgkin lymphoma Mediastinal B-cell lymphoma* HNSCC Urothelial carcinoma HCC* Gastric, GEJ, Esophageal cancer* Cervical cancer* Merkel cell carcinoma* MSI-H/dMMr mCRC High-risk NMIBC* Cutaneous SCC* | 2Â mg/kg Q3W up to 2Â years | 200Â mg Q3W or 400Â mg Q6W up to 2Â years | |
Adjuvant melanoma | 200Â mg Q3W up to 1Â year | 200Â mg Q3W or 400Â mg Q6W up to 1Â year | ||||
Pediatrics | 2Â mg/kg Q3W up to 2Â years | |||||
In combination with chemotherapy | mNSCLC HNSCC Esophageal cancer Advanced TNBC* | 2Â mg/kg Q3W up to 2Â years | 200Â mg Q3W or 400Â mg Q6W up to 2Â years | |||
In combination with trastuzumab and chemotherapy | Gastric, GEJ cancer* | |||||
In combination with axitinib | Advanced RCC | |||||
In combination with lenvatinib | Endometrial carcinoma* | |||||
Cemiplimab | ~19 days | Monotherapy | Cutaneous SCC BCC mNSCLC | 3Â mg/kg Q2W | 350Â mg Q3W | |
PD-L1 | Avelumab | ~4 days | Monotherapy | Metastatic Merkel cell carcinoma Urothelial cancer | 10Â mg/kg Q2W | 800Â mg Q2W |
In combination with axitinib | Advanced RCC | |||||
Atezolizumab | ~27 days | Monotherapy | Urothelial cancer mNSCLC | 1200Â mg Q3W | 840Â mg Q2W or 1200Â mg Q3W or 1680Â mg Q4W | |
In combination with nab-paclitaxel | Advanced TNBC | 840Â mg Q2W | ||||
In combination with bevacizumab and chemotherapy | mNSCLC | 1200Â mg Q3W | 840Â mg Q2W* or 1200Â mg Q3W or 1680Â mg Q4W* | |||
In combination with chemotherapy | mSCLC | |||||
In combination with bevacizumab | HCC | |||||
In combination with cobimetinib and vemurafenib | Advanced melanoma* | |||||
Durvalumab | ~18 days | Monotherapy | Unresectable NSCLC | 10Â mg/kg Q2W up to 1Â year | 10Â mg/kg Q2W or 1500Â mg Q4W up to 1Â year | |
|  | Patients < 30 kg | 10 mg/kg Q2W up to 1 year | ||||
In combination with chemotherapy | Extensive-stage SCLC | 1500Â mg Q3W for 4 doses followed by 1500Â mg Q4W | 1500Â mg Q3W for 4 doses followed by 1500Â mg Q4W | |||
|  | Patients < 30 kg | 20 mg/kg Q3W for 4 doses followed by 10 mg/kg Q2W | ||||